Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 30:21:2495-2501.
doi: 10.1016/j.csbj.2023.03.048. eCollection 2023.

Artificial intelligence and deep learning: New tools for histopathological diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Affiliations
Review

Artificial intelligence and deep learning: New tools for histopathological diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Yoshihisa Takahashi et al. Comput Struct Biotechnol J. .

Abstract

Nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is associated with metabolic syndrome and is rapidly increasing globally with the increased prevalence of obesity. Although noninvasive diagnosis of NAFLD/NASH has progressed, pathological evaluation of liver biopsy specimens remains the gold standard for diagnosing NAFLD/NASH. However, the pathological diagnosis of NAFLD/NASH relies on the subjective judgment of the pathologist, resulting in non-negligible interobserver variations. Artificial intelligence (AI) is an emerging tool in pathology to assist diagnoses with high objectivity and accuracy. An increasing number of studies have reported the usefulness of AI in the pathological diagnosis of NAFLD/NASH, and our group has already used it in animal experiments. In this minireview, we first outline the histopathological characteristics of NAFLD/NASH and the basics of AI. Subsequently, we introduce previous research on AI-based pathological diagnosis of NAFLD/NASH.

Keywords: Artificial intelligence; Machine learning; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Pathological diagnosis.

PubMed Disclaimer

Conflict of interest statement

We declare that there is no conflict of interest to disclose.

Figures

ga1
Graphical abstract
Fig. 1
Fig. 1
Steatosis in nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH). Macrovesicular steatosis is observed mainly in zone 3 (Masson’s trichrome staining).
Fig. 2
Fig. 2
Lobular inflammation in NASH. Inflammatory foci consisting of various inflammatory cells (lymphocytes, polymorphs, and Kupffer cells) are scattered in the hepatic lobule (arrows) (hematoxylin and eosin (H&E) staining).
Fig. 3
Fig. 3
Hepatocellular ballooning in NASH. Ballooned hepatocytes are observed as swollen hepatocytes with rarefied cytoplasm reflecting hepatocyte injury (arrows) (H&E staining).
Fig. 4
Fig. 4
Fibrosis in NASH. Perisinusoidal/pericellular (chicken wire) fibrosis is observed in the hepatic lobule (Masson’s trichrome staining).
Fig. 5
Fig. 5
Detection of steatosis and fibrosis in NASH by artificial intelligence (AI). (A) On the H&E staining slide, hepatic steatosis is observed mainly in zone 3. (B) Hepatic steatosis is accurately detected by AI and displayed in yellow. Non-steatotic area is displayed in green. (C) On the Masson’s trichrome staining slide, fibrotic area is stained blue. (D) Fibrotic area is accurately detected by AI and displayed in red. Non-fibrotic area is displayed in green. The insets show appearances in higher magnification.

Similar articles

Cited by

References

    1. Younossi Z., Tacke F., Arrese M., Sharma B.C., Mostafa I., et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672–2682. - PubMed
    1. Li J., Zou B., Yeo Y.H., Feng Y., Xie X., et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389–398. - PubMed
    1. Younossi Z.M., Stepanova M., Ong J., Trimble G., AlQahtani S., et al. Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States. Clin Gastroenterol Hepatol. 2021;19(3):.. 580-9.e5. - PubMed
    1. Fukusato T., Fukushima J., Shiga J., Takahashi Y., Nakano T., et al. Interobserver variation in the histopathological assessment of nonalcoholic steatohepatitis. Hepatol Res. 2005;33(2):122–127. - PubMed
    1. Younossi Z.M., Gramlich T., Liu Y.C., Matteoni C., Pertrelli M., et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol. 1998;11(6):560–565. - PubMed

LinkOut - more resources